My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

ImmunityBio, Inc. - Common Stock (NQ:IBRX)

2.198 +0.058 (+2.71%)

Streaming Delayed Price Updated: 10:26 AM EST, Nov 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ImmunityBio, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

7 Unknown Biotech Stocks That Could Rocket in 2023 ↗

September 23, 2022

Unknown biotech stocks that are poised for a big rally in 2023. Emerging biotech companies with a promising clinical pipeline.

Via InvestorPlace

Nikola, Super Micro Computer And Other Big Losers From Monday ↗

September 20, 2022

U.S. stocks closed higher with the Dow Jones gaining around 197 points on Monday. Here is the list of some big stocks recording losses in the previous session.

Via Benzinga

Twilio, AMTD Digital And Other Big Gainers From Wednesday ↗

September 15, 2022

U.S. stocks closed mostly higher with the Nasdaq 100 gaining around 100 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.

Via Benzinga

12 Health Care Stocks Moving In Monday's Intraday Session ↗

September 12, 2022

Via Benzinga

ImmunityBio Expects To Submit US Application For VesAnktiva In Bladder Cancer This Month ↗

April 04, 2022

ImmunityBio Inc (NASDAQ: IBRX)

Via Benzinga

Why KnowBe4 Shares Jumped Over 28%; Here Are 79 Biggest Movers From Yesterday ↗

September 20, 2022

Gainers Ventoux CCM Acquisition Corp. (NASDAQ: VTAQ) shares jumped 54.6% to settle at $7.05 on Monday.

Via Benzinga

Why Hill International Is Trading Higher By 15%; Here Are 30 Stocks Moving Premarket ↗

August 29, 2022

Gainers NewAge, Inc. (NASDAQ: NBEV) shares rose 19.7% to $0.2432 in pre-market trading. NewAge recently received Nasdaq notice on late filing of its form 10-Q.

Via Benzinga

Why Virios Therapeutics Is Trading Lower By Over 71%, Here Are 55 Stocks Moving In Monday's Mid-Day Session ↗

September 19, 2022

Gainers MicroCloud Hologram Inc. (NASDAQ: HOLO) shares jumped 134.6% to $19.74.

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗

August 03, 2022

Via Benzinga

Why Adobe Is Trading Lower By 17%, Here Are 49 Stocks Moving In Thursday's Mid-Day Session ↗

September 15, 2022

Gainers HeartBeam, Inc. (NASDAQ: BEAT) shares surged 58% to $1.96 after the company announced its patent for a 12-lead electrocardiogram patch monitor intended for detection of acute coronary syndrome...

Via Benzinga

Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗

July 29, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Vintage Wine Estates Shares Tumbled 40%; Here Are 70 Biggest Movers From Yesterday ↗

September 15, 2022

Gainers AMTD Digital Inc. (NYSE: HKD) shares jumped 311.8% to settle at $189.42 on Wednesday as the stock experienced a resurgence in momentum despite a lack of fundamental news.

Via Benzinga

Recap Of Thursday's Biotech Catalysts - End of The Day Summary ↗

July 28, 2022

Via Benzinga

Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.

Via Benzinga

FDA Accepts ImmunityBio's Bladder Cancer Candidate For Review ↗

July 28, 2022

The U.S. Food and Drug Administration (FDA) accepted for review ImmunityBio’s (NASDAQ: IBRX) Biologics License Application (BLA) for its lead asset N-803 in the treatment of patients with...

Via Benzinga

ImmunityBio Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma In Situ

July 28, 2022

From ImmunityBio

Via Business Wire

7 Best Pharmaceutical Stocks to Buy Now ↗

July 20, 2022

These investments represent the best pharmaceutical stocks. Each offers incredible upside potential in the post-pandemic world.

Via InvestorPlace

ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

June 06, 2022

From ImmunityBio, Inc.

Via Business Wire

ImmunityBio Submits Biologics License Application for N-803 Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

May 23, 2022

From ImmunityBio, Inc.

Via Business Wire

7 Cheap Biotech Stocks to Buy Now ↗

May 19, 2022

These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains.

Via InvestorPlace

ImmunityBio To Present Data From Multiple Clinical Trials at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

April 28, 2022

From ImmunityBio, Inc.

Via Business Wire

99 Biggest Movers From Yesterday ↗

May 12, 2022

Gainers Armstrong Flooring, Inc. (NYSE: AFI) shares jumped 237% to settle at $0.49 on Wednesday after a 13D filing showed Esopus Creek Advisors LLC disclosed a 5.1% active stake in the company.

Via Benzinga

ImmunityBio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

April 25, 2022

From ImmunityBio, Inc.

Via Business Wire

Global Antibiotic Resistance Market to Hit US$16.5 Billion By 2030

April 21, 2022

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from...

Via FinancialNewsMedia

ImmunityBio Provides Updated Status of Biologics License Application (BLA) for VesAnktiva Plus BCG for Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

April 01, 2022

From ImmunityBio, Inc.

Via Business Wire

Bonds Are Screaming “Recession.” That’s Great News For One Top Sector. ↗

March 29, 2022

The 10-2 year treasury yield spread is close to zero. Here's what you should do about this warning sign of a coming recession.

Via InvestorPlace

Development of Novel Innovative Diagnostic tests Generating Huge Revenue Opportunity for Global Blood Testing Market

February 16, 2022

Palm Beach, FL – February 16, 2022 – FinancialNewsMedia.com News Commentary – The global blood testing market has grown during the pandemic and is expected to continue to rise in the coming years....

Via FinancialNewsMedia

ImmunityBio's Ankitva Shows 100% Survival At Two Years In Bladder Cancer Setting ↗

February 15, 2022

ImmunityBio Inc (NASDAQ: IBRX) announced data from its bladder cancer trial (QUILT-3.032) Phase 2/3 study of intravesical BCG plus Anktiva (N-803). The data showed...

Via Benzinga

ImmunityBio Completes Acquisition of Athenex’s Interest in Dunkirk, New York Advanced Biotech Manufacturing Facility

February 15, 2022

From ImmunityBio, Inc.

Via Business Wire

The Daily Biotech Pulse: Larimar Plunges On Extension Of Clinical Hold, ImmunityBio Gains On Positive Data, Adcom Test Awaits Avenue Therapeutics ↗

February 15, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus ImmunityBio Says Cancer Combo Therapy Produces Positive Results In Late-Stage...

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.